SIRT1 and cardiovascular disorder: However, the therapeutic indications of resveratrol mainly target diabetes and cardiovascular diseases rather than bone-related diseases, and since resveratrol is not a specific agonist of SIRT1, its multiple off-target effects are a key factor to be considered.